Impact BioMedical Inc. (IBO)Healthcare | Biotechnology | Houston, United States | NYSE American
0.44 USD
+0.00
(0.612%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.44 |
Hot Take ↕ | Aug. 22, 2026, 4:26 a.m. EDT
The immediate outlook is severely clouded by a deteriorating balance sheet and collapsing operational metrics. Despite a recent price bounce, the company is burning cash with negative operating cash flow and a current ratio of just 0.156, indicating severe liquidity stress. Revenue has plummeted by nearly 57%, and the business is generating massive losses relative to sales, suggesting the core product or service model is failing to gain traction. The 'Going Concern' qualification in the latest audit is a critical red flag, signaling that management doubts the company can survive without further capital infusion. While retail traders are pushing the price up on merger rumors, this is a classic speculative pump rather than a sign of sustainable value. With no dividend history and a market cap of only $51 million, there is no safety net. The statistical forecast models also show very low confidence in any upward movement, reinforcing the view that the recent price action is noise rather than a trend reversal. Investors should avoid this security due to the high probability of dilution or insolvency. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.101655 |
| AutoETS | 0.138857 |
| MSTL | 0.140034 |
| AutoARIMA | 0.160807 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 6.22 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.053 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.492 |
| Market Cap | 47,840,280 |
| Trailing P/E | 0.50 |
| Profit Margins | 2260.00% |
| Website | https://www.impactbiomedinc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.265 |
| Address1 | 1,400 Broadfield Blvd. |
| Address2 | Suite 130 |
| All Time High | 6.17 |
| All Time Low | 0.362 |
| Ask | 0.46 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 34,160 |
| Average Daily Volume3 Month | 53,517 |
| Average Volume | 53,517 |
| Average Volume10Days | 34,160 |
| Bid | 0.4412 |
| Bid Size | 3,300 |
| Book Value | 0.1 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4437 |
| Current Ratio | 0.156 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.4533 |
| Day Low | 0.442 |
| Debt To Equity | 9.492 |
| Display Name | Impact BioMedical |
| Ebitda | -3,952,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.924 |
| Enterprise To Revenue | 1,459.322 |
| Enterprise Value | 51,076,280 |
| Eps Trailing Twelve Months | 0.89 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.45898 |
| Fifty Day Average Change | -0.015280008 |
| Fifty Day Average Change Percent | -0.033291228 |
| Fifty Two Week Change Percent | -26.499998 |
| Fifty Two Week High | 0.83 |
| Fifty Two Week High Change | -0.3863 |
| Fifty Two Week High Change Percent | -0.4654217 |
| Fifty Two Week Low | 0.37 |
| Fifty Two Week Low Change | 0.07369998 |
| Fifty Two Week Low Change Percent | 0.19918914 |
| Fifty Two Week Range | 0.37 - 0.83 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,493,400,000 |
| Float Shares | 11,488,352 |
| Free Cashflow | 1,016,875 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 2 |
| Fullday Change | 0.00269997 |
| Fullday Change Percent | 0.612238 |
| Fullday Price | 0.4437 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -389,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.89018995 |
| Held Percent Institutions | 0.03558 |
| Implied Shares Outstanding | 107,821,231 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc |
| Long Name | Impact BioMedical Inc. |
| Market | us_market |
| Market Cap | 47,840,280 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_644355879 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 791,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 47,549,162 |
| Open | 0.4437 |
| Operating Cashflow | -508,000 |
| Operating Margins | -234.0 |
| Payout Ratio | 0.0 |
| Phone | 281 415 6576 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.4437 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 0.441 |
| Price Hint | 4 |
| Price To Book | 4.437 |
| Price To Sales Trailing12 Months | 1,366.8651 |
| Profit Margins | 22.6 |
| Quick Ratio | 0.005 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00269997 |
| Regular Market Change Percent | 0.612238 |
| Regular Market Day High | 0.4533 |
| Regular Market Day Low | 0.442 |
| Regular Market Day Range | 0.442 - 0.4533 |
| Regular Market Open | 0.4437 |
| Regular Market Previous Close | 0.441 |
| Regular Market Price | 0.4437 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 6,681 |
| Return On Assets | -0.17787 |
| Return On Equity | 0.23462 |
| Revenue Growth | -0.571 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 107,821,231 |
| Shares Percent Shares Out | 0.0050999997 |
| Shares Short | 546,651 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 557,404 |
| Short Name | Impact BioMedical, Inc. |
| Short Percent Of Float | 0.0465 |
| Short Ratio | 17.87 |
| Source Interval | 15 |
| State | TX |
| Symbol | IBO |
| Total Cash | 10,000 |
| Total Cash Per Share | 0.0 |
| Total Debt | 0 |
| Total Revenue | 35,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.89 |
| Trailing P E | 0.49853933 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.51496 |
| Two Hundred Day Average Change | -0.071260005 |
| Two Hundred Day Average Change Percent | -0.1383797 |
| Type Disp | Equity |
| Volume | 6,681 |
| Website | https://www.impactbiomedinc.com |
| Zip | 77,084 |